A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

The companies also hope to steal market share from Novo Nordisk, undercutting the long-acting Levemir (insulin detemir) by 21% and Tresiba (insulin degludec) an ultra long-acting insulin ...

(Reuters) - Novo Nordisk (NYSE:NVO) said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, ...